Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on January 13, 2025, providing preliminary financial results for the fourth quarter and full year 2024, alongside initial guidance for 2025. The company reported approximately $451 million in preliminary fourth-quarter 2024 global net product revenues and $1,646 million for the full year 2024, driven by its key therapies ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. These preliminary figures offer investors an early look at the company's performance ahead of its complete financial results announcement in February 2025. Alnylam has also set forth its product and pipeline goals for 2025, including revenue guidance and non-GAAP operating income guidance, signaling its strategic direction and financial outlook for the upcoming year. Investors should note that these preliminary results are unaudited and subject to adjustments.
Key Highlights
- 1Preliminary Q4 2024 global net product revenues estimated at approximately $451 million.
- 2Preliminary Full Year 2024 global net product revenues estimated at approximately $1,646 million.
- 3Key therapeutic areas contributing to revenue include ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®.
- 4Company has provided its 2025 product and pipeline goals.
- 52025 combined net product revenue guidance has been announced.
- 62025 non-GAAP operating income guidance has been provided.
- 7Preliminary financial results are unaudited and subject to adjustment.